Cellectis

From all of us at Cellectis, we wish you a joyous holiday season! May this festive period bring you moments of joy, reflection, and well-deserved rest. As we look ahead to the New Year, we're filled with optimism for the groundbreaking advancements we'll achieve together in our mission to transform the lives of patients with blood cancers. #HappyHolidays

What if we turn our immune system into cancer killing commandos? Cancer is a nasty disease – it involves the uncontrolled proliferation of abnormal cells that can invade and spread throughout the body, disrupting normal organ function. What if instead of using chemicals, we use our immune system – our T cells - to hunt the cancer cells inside the body? Our battle plan: 1 - Collect T-cells from healthy donor 2 - Genetically modify the T-cells using TALEN® gene editing technology to target cancer cells 3 - Create an army of specialized cancer-targeting T-cells 4 - Deploy the killer cells against tumors in the body Why it’s a good plan? ✅ Safe, precise, efficient : TALEN® is one of the most precise tool existing in the gene editing field ✅ The CAR T-cells are manufactured internally from A to Z to ensure consistency and quality control ✅ One donor, multiple patients: the off-the-shelf approach allows to treat numerous patients with cells from a single healthy donor, maximizing efficiency and reach. ✅ Off-the-shelf therapy ready to deploy immediately, potentially saving crucial time for patients who need immediate treatment. It's the future of cancer treatment - where we don't just fight cancer, we precisely target and eliminate it. Thanks TEDxSaclay for reposting this video archive! Link to watch the TEDx video: https://lnkd.in/eVz6BnYp

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB). To read the press release: https://lnkd.in/e8B3tbDs

Pourquoi la thérapie génique est-elle la médecine du futur ?  Dans cette deuxième vidéo, Andre Choulika Ph.D., directeur général de Cellectis, partage sa vision sur les perspectives d’avenir qu’offrent les thérapies géniques et nous explique comment cette nouvelle approche, longtemps fantasmée, devient réalité.  Désormais capable de réparer des gènes défectueux et de détruire les cellules cancéreuses, la thérapie génique offre de nouvelles solutions pour des patients sans traitement jusqu’alors et dans de nombreux domaines thérapeutiques : l’oncologie, l’immunologie, la neurologie, et les maladies rares ou orphelines. Les principaux enjeux selon lui ? La sécurité des traitements et la capacité de cibler précisément les bons tissus ou organes pour garantir une efficacité optimale.

As we take a moment to reflect on what we’re thankful for this season, all of us at Cellectis want to express our heartfelt gratitude to: 🍁 Our dedicated colleagues whose passion drives groundbreaking advancements in cancer therapy. 🍁 Patients: your strength and resilience inspire us every day. 🍁 Our valued partnerships: we are grateful for the collaboration and trust of our partners who believe in our vision. As we gather with loved ones, let’s cherish the moments of connection and hope. We look forward to continuing this journey together, making strides toward a brighter future for all those affected by cancer. Wishing you a joyful and fulfilling 🍂#Thanksgiving 🍂 filled with warmth and gratitude!

Breast cancer is the most prevalent malignancy in women.   Among all subtypes, triple-negative breast cancer (TNBC) stands out as the most aggressive form with high metastatic potential and poor survival rates.   Surgery, chemotherapy and radiation therapy continue to be the standard of care, and their success remains limited.   Allogeneic CAR T cells could hold promises for patients, but the therapy faces significant hurdles in treating solid tumors such as TNBC.   Here's why: ❌ Tumor Microenvironment: solid tumors create a hostile environment that suppresses immune cell function. This includes physical barriers, immunosuppressive cells, and metabolic challenges that hinder CAR T cell efficacy.   ❌ T Cell Trafficking: CAR T cells struggle to penetrate solid tumor masses due to abnormal vasculature and stromal barriers. This limits their ability to reach and eliminate cancer cells.   ❌ Persistence and Functionality: the immunosuppressive nature of solid tumors can lead to rapid exhaustion of CAR T cells, reducing their long-term effectiveness.   Despite all this, tumor-associated MUC1 antigen is overexpressed in a large number of advance-stage TNBC patients thus offering a distinct target for treatment.   Our proposition:   ✅ We have created a multi-layered CAR T-cell engineering strategy using TALEN® and synthetic biology to multi-armor CAR T-cells with synergistic functionalities to overcome the immunosuppressive tumor microenvironment (TME) of solid tumors.   ✅ We demonstrate enhanced cytotoxic activity of MUC1 CAR T-cells armored with PD1KO, tumor-specific IL12 release and TGFBR2KO attributes, all of them catered towards the TNBC TME, in intravenous and intratumoral mouse models.   ✅ Our results show that TALEN®-mediated multiplex editing can support CAR T-cells in effectively mounting an anti-tumor response to clear breast tumors.   To know more about the study: https://lnkd.in/gbswKV7g #celltherapy #genetherapy

This week, meet Andre Choulika Ph.D., CEO of Cellectis and Arthur Stril, Interim Chief Financial Officer, at Jefferies London Healthcare Conference. #celltherapy #genetherapy

Here is what happen when you co-culture T-cells and cancer cells:   Just as an ant farm allows us to observe ant behavior in a controlled environment, co-culturing T-cells and cancer cells creates a miniature "immune system vs. tumor" battleground in the lab.   In this video: Blue shows the position of target cells Red the position of T cells and Yellow when there are T-cell interaction   Confined Space:  Like ants in their farm, cells interact within a defined area.   Observable Interactions:  We can watch T-cells "hunt" cancer cells in real-time.   Controlled Environment:  Researchers manipulate conditions to study different scenarios.   Complex Behaviors:  Both systems reveal intricate social dynamics and survival strategies.   Why It Matters: This "cellular ant farm" helps us understand how our immune system fights cancer and how tumors evade attack. It's a crucial tool for developing more effective immunotherapies. Thanks to Nanolive SA for the great video!

En novembre 2023, nous avions annoncé un partenariat stratégique entre AstraZeneca et Cellectis, biotech française spécialisée dans l’édition du génome, afin de développer la prochaine génération de produits de thérapie cellulaire et génique en oncologie, en immunologie et dans les maladies rares. Pour célébrer la première année de cette collaboration, nous avons invité André Choulika, directeur général de Cellectis, dans nos locaux pour répondre aux questions de nos collaborateurs. Devant l’enthousiasme des équipes, nous avons souhaité en tirer non pas une, mais deux vidéos, tant le contenu qu’il a partagé est riche et enthousiasmant. Je vous propose aujourd'hui de découvrir la première vidéo, qui dresse un état des lieux de ce partenariat, ainsi que les motivations et les ambitions de notre alliance. Rendez-vous prochainement pour la seconde vidéo ! Un grand merci à André pour sa présence et ses propos porteurs d’espoir pour de nombreux patients.

Sickle cell disease (SCD) affects 5 million people worldwide, making it one of the most common inherited blood disorders.   Recent breakthroughs in gene therapy have ushered in a new era of hope for SCD patients, offering a potential cure by addressing the genetic root of the disease.   Here is Cellectis’ approach to treat the disease, using TALEN® gene editing tool.   As we move forward, it's essential to continue educating ourselves and others about the potential groundbreaking treatments.   By bridging the knowledge gap, we can ensure that patients and healthcare providers make informed decisions about the future of SCD treatment.   To learn more about the research, follow this link: https://lnkd.in/e68HPhaS